Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

Antimicrobial treatments for extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections have proven lackluster, while dosing challenges in patients receiving continuous renal replacement therapy continue. We describe a patient receiving cefiderocol, ampicillin/sulbactam, and tigecycline...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobic, Emir, Abouelhassan, Yasmeen, Singaravelu, Kumara, Nicolau, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Novel Id Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547507/
https://www.ncbi.nlm.nih.gov/pubmed/36225744
http://dx.doi.org/10.1093/ofid/ofac484
Descripción
Sumario:Antimicrobial treatments for extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections have proven lackluster, while dosing challenges in patients receiving continuous renal replacement therapy continue. We describe a patient receiving cefiderocol, ampicillin/sulbactam, and tigecycline for XDR-AB while undergoing continuous venovenous hemodiafiltration. The clinical course, cefiderocol and sulbactam pharmacokinetics, and synergy assessments are described.

Ejemplares similares